Eli Lilly

Johnson & Johnson

McKesson

Bristol-Myers

AbbVie

CoreSite Realty

Merck

Zoetis

Pfizer

Viatris

VanEck Vectors Pharmaceutical ETF

PPH tracks a market-cap-weighted index of 25 of the largest global pharmaceutical firms.

iShares U.S. Healthcare Providers ETF

Invesco Dynamic Pharmaceuticals ETF

Investors looking for equities suddenly have more than a few options to consider in this mini-market rally. Whether markets have really priced in Fed action or a possible recession already or not, investors should take a look at healthcare ETFs offering consistency in a strong year for health insurers and pharmaceutical firms.

3 ETFs for the Healthcare Sector's Highs

The healthcare sector isn't setting the investment world ablaze this year, but it is outperforming the broader market, underscoring its defense posture.

This ETF Is Home to Some of the Top Healthcare Stocks

PPH investors own the whole world of bigger to big pharma, where wallet share is primarily in the U.S. Things are changing, however, with Medicare now able to negotiate prices with companies on the most expensive drugs for seniors starting in 2026.

PPH Investors Should Keep On Top Of Regulatory Developments

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

iShares Nasdaq Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Medical Devices ETF

iShares U.S. Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

Vanguard Health Care ETF

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs for Medicare prescriptions at $2,000 per year, starting in 2025.

What The Inflation Reduction Act Means For Drug Prices

This is a mid-term election year, meaning that some familiar issues investors should be aware of are popping up yet again. That includes reducing pharmaceutical prices.

Pharma Stocks, ETFs Can Deal With Drug Pricing Legislation

First Trust Morningstar Dividend Leaders Index Fund

Invesco KBW Property & Casualty Insurance ETF

Invesco Dynamic Energy Exploration & Production ETF

While there have been losers in many corners of the space, we highlight five ETFs from different industries that have gained in the first half of the year.

Wall Street on Track for Worst 1H: 4 Top-Ranked ETFs Win

First Trust Nasdaq Pharmaceuticals ETF 

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Q1 Earnings

Historically, PPH generated a steady total return with a low yield up to 2 percent. PPH's price multiples are considerably lower than its peers and index despite strong earnings and stable historical price growth.

PPH: A Pharmaceutical ETF Delivering Close To 10% Total Return

GlaxoSmithKline

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Sanofi

The pending separation of consumer care businesses by pharmaceutical companies is understandable and may offer investment opportunities.

Pharma In Transition: Context And Opportunities

Solid earnings failed to impress pharma ETFs over the past month due to a broad sell-off in the market.

Solid Q4 Earnings Fail to Impress Pharma ETFs

Pharmaceuticals stocks and the related exchange traded funds are benefiting from the now-steady revenue stream provided by coronavirus vaccines, but with that priced into many pharmaceuticals equities, analysts and investors are looking for more. Fortunately for investors considering ETFs such as the VanEck Vectors Pharmaceutical ETF (PPH), the 2022 outlook is bright, and that includes [.

Pharmaceuticals Stocks, ETFs Could Have Power Beyond 2022

Broadly speaking, the healthcare sector delivered some decent though not spectacular performances last year, with diversified exchange traded funds addressing the sector hindered by rough showings by biotechnology equities. With near-term prospects for a biotechnology rebound somewhat murky — it's possible, but it will take time — and shares of medical device makers pricey, pharmaceuticals stocks may [.

Pharma Could Be Place to Be for Healthcare Winners, Value

Pharmaceuticals stocks and the related exchange traded funds are turning solid performances in 2021. Investors looking for quality and growth traits might want to continue leaning on this corner of the healthcare sector in 2022.

Pharma Could Be Fabulous in 2022

Domestic dividend growth is on a torrid pace this year, and market observers expect that the trend will continue in 2022. Investors searching for sector and industry exchange traded funds with which to access baskets of impressive dividend growers ought to consider healthcare, namely pharmaceuticals equities.

Write a Prescription for Pharma Dividends With PPH

According to reports out Wednesday, the first U.S case of the Omicron variant of the coronavirus was discovered in California. More research is needed on the Omicron strain, but there's already ample chatter that it could require booster shots or perhaps even its own vaccine, signaling a variety of investment implications.

Omicron Variant Could Be Potent for Pharma Stocks, ETFs

Blue-chip pharmaceuticals stocks are turning solid showings this year, but the group is lagging the broader market, indicating that some of the coronavirus vaccine blush is wearing off the group. However, some market observers see avenues for big pharma equity upside in 2022 and, if accurate, that would be constructive for exchange traded funds, such [.

There's Power Lurking in This Pharma ETF

Healthcare stocks are solid but not spectacular performers. For example, the S&P 500 Health Care Index is higher by more than 17%, though that lags the broader market.

PPH Pertinent as Some Cheap Pharma Stocks Offer Big Dividend Growth

The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.

Wave of Solid Q3 Earnings Push Pharma ETFs Higher

There are multiple coronavirus vaccines on the market, and with the likelihood of booster shots increasing by the day, the revenue outlook for healthcare exchange traded funds, including the VanEck Vectors Pharmaceutical ETF (PPH), is improving. PPH tracks the MVIS US Listed Pharmaceutical 25 Index and is home to 25 stocks, several of which are [.

Strong Vaccine Demand Lifting Pharma Sales

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

Pharma ETFs Gain on Q2 Earnings

Biogen's (NASDAQ: BIIB) Aduhelm sparked a rally in the biotech giant's share price and hope that progress is being made in treating Alzheimer's. However, the news isn't free of controversy, and carries with it implications for healthcare exchange traded funds, including the VanEck Vectors Pharmaceutical ETF (PPH).

Alzheimer's Drug Cost Pushes Pharmaceutical Prices Back Into the Spotlight

First Trust Health Care AlphaDEX Fund

iShares Evolved U.S. Innovative Healthcare ETF

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

Pharma & Healthcare ETFs at a One-Year High: Here's Why

The pharmaceuticals industry got a boost last year when a Covid-19 vaccine was introduced, but artificial intelligence (AI) could keep the sector and ETFs like the VanEck Vectors Pharmaceutical ETF (PPH) going. AI technology is making its way into a number of industries, including pharmaceuticals.

Artificial Intelligence Set to Transform the Pharmaceutical Industry

Virtus LifeSci Biotech Products ETF

Principal Healthcare Innovators Index ETF

Loncar Cancer Immunotherapy ETF

Direxion Daily Healthcare Bull 3x Shares

First Trust NYSE Arca Biotechnology Index Fund

Fidelity MSCI Health Care ETF

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

abrdn Healthcare Investors 

abrdn Life Sciences Investors 

Defiance Nasdaq Junior Biotechnology ETF

John Hancock Multifactor Healthcare ETF

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Global X Longevity Thematic ETF

ProShares UltraShort Health Care

ProShares Ultra Health Care

Invesco S&P 500 Equal Weight Health Care ETF

Pacer BioThreat ETF

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.

News for VanEck Vectors Pharmaceutical ETF ETF (PPH)